GREENLAND MINES LTD Research and Development Expense
GREENLAND MINES LTD (GRML) reported Research and Development Expense of $400.54 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-17
- GREENLAND MINES LTD research and development expense for the quarter ending 2026-06-30 was $400.54K, a 67.80% increase year-over-year.
- GREENLAND MINES LTD research and development expense for the quarter ending 2026-03-31 was $321.27K.
- GREENLAND MINES LTD research and development expense for the quarter ending 2025-12-31 was $124.34K.
- GREENLAND MINES LTD research and development expense for the quarter ending 2025-09-30 was $271.14K.
- GREENLAND MINES LTD research and development expense for fiscal 2025 was $634.19K.
- GREENLAND MINES LTD research and development expense for fiscal 2024 was $0.00.
- GREENLAND MINES LTD research and development expense for fiscal 2023 was $0.00.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $400.54K 10-Q · filed 2026-08-17 | $721.81K 10-Q · filed 2026-08-17 | $846.15K derived: sum of 3 quarters · filed 2026-08-17 | $1.12M derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $321.27K 10-Q/A · filed 2026-08-14 | $445.61K derived: sum of 2 quarters · filed 2026-08-14 | $716.76K derived: sum of 3 quarters · filed 2026-08-14 | $955.46K derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-12-31 | $124.34K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $395.49K derived: sum of 2 quarters · filed 2026-08-14 | $634.19K derived: sum of 3 quarters · filed 2026-08-17 | $634.19K 10-K/A · filed 2026-08-14 |
| 2025-09-30 | $271.14K 10-Q · filed 2025-11-13 | $509.85K derived: sum of 2 quarters · filed 2026-08-17 | $509.85K 10-Q · filed 2025-11-13 | $509.85K derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-06-30 | $238.70K 10-Q · filed 2026-08-17 | $238.70K 10-Q · filed 2026-08-17 | $238.70K derived: sum of 3 quarters · filed 2026-08-17 | $238.70K derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-05-15 | $0.00 derived: sum of 3 quarters · filed 2025-05-15 | $0.00 derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-19 | $0.00 derived: sum of 2 quarters · filed 2024-11-19 | $0.00 10-Q · filed 2024-11-19 | $0.00 derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-19 | $0.00 10-Q · filed 2024-08-19 | $0.00 derived: sum of 3 quarters · filed 2025-05-15 | $0.00 derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-05-15 | $0.00 derived: sum of 3 quarters · filed 2025-05-15 | $0.00 derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-19 | $0.00 derived: sum of 2 quarters · filed 2024-11-19 | $0.00 10-Q · filed 2024-11-19 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-19 | $0.00 10-Q · filed 2024-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |